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Heparin-binding EGF-like growth factor (HB-EGF) is a member of the EGF family that binds to and activates EGF receptor, and is expressed in a
variety of tissues, predominantly in the lung, heart, brain and skeletal muscle. HB-EGF is known to induce vascular smooth muscle cell (VSMC)
proliferation by activating PI3K-Akt andMAPK pathway. However, our preliminary data showed that Janus kinase-signal transducers and activators
of transcription (JAK-STAT) pathway was also involved in HB-EGF induced VSMC proliferation. More interestingly, HB-EGF (10 ng/ml) induced
a biphasic activation of STAT3 (early at 5 min and late at 60–120 min). Therefore, we tried to elucidate the underlying mechanism of this delayed
STAT3 activation by HB-EGF in VSMCs. First, we examined the effect of HB-EGF on interleukin-6 (IL-6) mRNA expressions, since IL-6 have
been implicated in the regulation of STAT3 activation. According to our data, HB-EGF increased transcription of IL-6, cardiotrophin-1 (CT-1),
leukemia inhibitory factor (LIF) and ciliary neurotrophic factor (CNTF). The secretion of IL-6 was also increased by HB-EGF. Furthermore, these
HB-EGF-mediated up-regulation of IL-6 mRNA expression and secretion were inhibited by NF-κB inhibitor Bay117082 (2.5 μM) treatment
suggesting involvement of NF-κB pathway. Again, the late activation of STAT3 by HB-EGF was abolished by both Bay117082 and IL-6
neutralizing antibody (1 μg/ml) indicating IL-6 is a key molecule in the delayed activation of STAT3 by HB-EGF. In addition, IL-6 neutralizing
antibody inhibited both HB-EGF conditioned media induced STAT3 activation and HB-EGF induced VSMC proliferation. In conclusion, IL-6 plays
an important role in the delayed activation of STAT3 and VSMC proliferation induced by HB-EGF.
© 2007 Published by Elsevier B.V.Keywords: HB-EGF; Proliferation; STAT3; IL-6; Smooth muscle cell1. Introduction
Vascular smooth muscle cell (VSMC) proliferation induced
by various growth factors has been implicated in a wide variety
of pathological processes including atherosclerosis, hyperten-
sion, and restenosis [1]. The role of growth factors such as
platelet-derived growth factor (PDGF), basic fibroblast growth
factor (bFGF), and epidermal growth factor (EGF) in inducing
VSMC proliferation and intimal thickening is well recognized
[2–4]. Heparin-binding EGF-like growth factor (HB-EGF) is a
member of the EGF family that binds to and activates EGF
receptor (EGFR), and is expressed in a variety of tissues, pre-
dominantly in the lung, heart, brain and skeletal muscle [5–8]. It⁎ Corresponding author. Tel.: +82 2 380 1534; fax: +82 2 388 0924.
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doi:10.1016/j.bbamcr.2007.07.001has been reported that the transcript level of HB-EGF was
increased approximately 12-fold within 2 h after balloon injury
and 3-fold even after 14 days [9]. Also HB-EGF has been
reported to be significantly expressed in VSMC and macro-
phages of the atherosclerotic plaques [10]. HB-EGF is known to
activate cell signal transduction networks by auto-phosphory-
lation of EGF receptor which consequently recruits adapter
signaling molecules. In those cell signal networks, MAP kinase
pathway and PI3K-Akt pathway are well known [11,12]. Our
preliminary study indicates JAK-STAT pathway also partici-
pates in HB-EGF induced VSMC proliferation, relatively less
information is known to date. Thus, in the present study, we
tried to elucidate and characterize a novel pathway in HB-EGF
induced VSMC proliferation focusing on JAK-STAT pathway.
According to our data, HB-EGF treatment increased STAT3
phosphorylation as early as 5 min in VSMCs then decreased to
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was increased again. Although such delayed STAT3 phosphor-
ylation by angiotensin II (AngII) or isoproterenol in cardio-
myocytes has been reported [13,14], no previous study reported
such delayed STAT3 phosphorylation in VSMC, especially by
HB-EGF treatment. It has been reported that JAK-STAT path-
way may play a critical role in regulating biologic responses to
cytokine stimulation, including cellular proliferation, differen-
tiation, and survival [15]. Upon activation, the JAK phosphor-
ylates the latent cytoplasmic transcription factors, the STATs,
resulting in STAT dimerization and subsequent translocation to
the nucleus where they regulate the expression of related genes
[16]. Activation of STAT proteins has been reported in cells
treated with various cytokines, growth factors, insulin, and
AngII [17–19]. IL-6, which belongs to IL-6 family cytokine
with other cytokines such as cardiotrophin-1 (CT-1), leukemia
inhibitory factor (LIF), ciliary neurotrophic factor (CNTF),
oncostatin M, and interleukin-11, is an important factor known
to activate STAT3. Using a common receptor subunit gp130,
these cytokines act on complex cellular processes such as gene
activation, VSMC proliferation, B cell differentiation and T cell
activation [20–22]. Furthermore, IL-6 is proposed to play an
important role in atherosclerosis and coronary restenosis [23–
25]. There are also studies reported that IL-6 was secreted from
SMC and it induced VSMC proliferation by acting as an
autocrine or paracrine factor [26–28]. Regarding the relation
between the EGF family and IL-6, it has been reported that IL-6
increased myeloma cell growth by secreting HB-EGF [29] and
there is also a study reported that EGF and TGFα increased
biological activity of IL-6 in thymocyte [30]. However, it is
hard to generalize the relation between the EGF family and IL-6
because more recent study reported that HB-EGF decreased
serum IL-6 after intestinal ischemia/reperfusion injury [31].
In the present study, we examined the hypothesis that IL-6 is
a key factor that mediates HB-EGF induced delayed STAT3
activation. Based on our findings, we suggest that IL-6 plays
important roles in the delayed activation of STAT3 and VSMC
proliferation induced by HB-EGF.2. Materials and methods
2.1. Reagents
Cell culture reagents and oligo(dT)12–18 were from InVitrogen (Carlsbad,
CA). Mouse monoclonal antibody against β-actin was purchased from Sigma
(St. Louis, MO). Peroxidase-conjugated anti-rabbit secondary antibody and anti-
mouse secondary antibody were from Jackson ImmunoResearch (West Grove,
PA). Accupower RT premix and Accupower PCR premix were purchased from
Bioneer (Seoul, Korea). HB-EGF and IL-6 neutralizing antibodies were pur-
chased from R&D systems (Minneapolis, MN). RNeasy mini kit was from
Qiagen (Valencia, CA). p65 antibody and gp130 antibody were from SantaCruz
(Santa Cruz, CA) and IκBα antibody was from Cell signaling (Danvers, MA).
2.2. Cell culture
Rat vascular smooth muscle cells (rVSMCs) were isolated from the thoracic
aorta of Sprague–Dawley rats (200–250 g; ORIENT-Charles River Technology,
Seoul, Korea) by using the method described previously [32]. More than 95% of
the cells were positive for α-actin and exhibited the typical hill-and-valleymorphology of SMCs. In this study, passages between 5 and 10 were used for
the experiments. Cells were maintained in DMEM containing 10% FBS. For
various signal inhibitor treatment, cells were starved in DMEM (0.1% FBS) for
24 h and then treated with appropriate inhibitors 1 h prior to HB-EGF treatment.
2.3. Cellular proliferation assay
Cells were seeded at 1×104 cells/well in 96-well plates and starved for 24 h in
DMEM containing 0.1% FBS before any treatment. After the cells were treated
with HB-EGF and cultured for additional 24 h, DNA synthesis was determined
by BrdU-incorporation assay using commercial ELISA kit according to the
manufacturer's instructions (Roche, Penzberg, Germany). The absorbance at
450 nm was determined using a microplate reader with SOFTmax PRO software
(Molecular Devices, Sunnyvale, CA).
2.4. Western blot analysis
Cells were starved for 24 h in DMEM containing 0.1% FBS before any
treatment. Equal amounts of cell lysates were separated by SDS-PAGE gel.
Membranes were incubated with appropriate primary antibodies, and the im-
munopositive bands were visualized by ECL system (Amersham Biosciences,
Buckinghamshire, England). Each experiment was triplicated at least. Nuclear
extracts were prepared by using the method described previously with little
modification [33].
2.5. Reverse transcriptase polymerase chain reaction analysis
Total RNA from rVSMC was extracted with RNeasy mini kit according to
the manufacturer's recommendations. From 500 ng of total RNA, cDNAs were
synthesized using oligo (dT)12–18 primer and Accupower RT premix. PCR was
done using Accupower PCR premix. Rat IL-6, CT-1, LIF, CNTF and β-actin
mRNA were amplified by PCR using the following primers: rat IL-6, 5′-GAC
TTC ACA GAG GATACC ACC C-3′ and 5′-CTC TGA ATG ACT CTG GCT
TTG TC-3′; rat CT-1, 5′-CCC TCT TCA CCT CCA ACA GTG-3′, 5′-GAG
GCG AGA GCA GAA GAG AA-3′, rat LIF, 5′-AGT CAA CTG GCT CAA
CTC AAC G-3′, 5′-CTG GAC CAC CGC ACTAAT GAC T-3′, rat CNTF, 5′-
GCA AAC ACC TCT GAC CCT TC-3′, 5′-AAA GGC AGA AAC TTG GAG
CA-3′, rat β-actin, 5′-CCC ATT GAA CAC GGC ATT GTC-3′and 5′-CGC
ACG ATT TCC CTC TCA GC-3′.
2.6. ELISA for IL-6
An ELISA kit for detection of rat IL-6 was purchased from R&D systems.
Cells were seeded at 3×106 cells in 100 mm culture dish and starved for 24 h in
DMEM containing 0.1% FBS before any treatment. At various time points after
HB-EGF treatment (10 ng/ml), 50 μl of culture media were analyzed for the
presence of IL-6 according to the manufacturer's instructions. The absorbance at
450 nm was determined using a microplate reader with SOFTmax PRO software
(Molecular Devices, Sunnyvale, CA).
2.7. Statistical analysis
The values are mean±SEM. Statistical analyses were performed byANOVA,
followed by the Student–Newman–Keuls test. Differences with a value of
Pb0.05 were considered statistically significant.3. Results
3.1. HB-EGF induces phosphorylation of STAT3 in VSMCs and
HB-EGF-induced cell proliferation was inhibited by JAK-STAT
pathway inhibitor
To determine whether JAK-STAT pathway participates in
HB-EGF induced signal transduction in VSMC, VSMCs were
Fig. 1. HB-EGF induced VSMC proliferation involves EGFR and JAK-STAT pathway. (A) Upper panel: VSMCs were stimulated with HB-EGF (10 ng/ml), and
collected at the time indicated. The cell lysates were subjected to western blot using p-STAT3 antibody. Lower panel: the intensity of the corresponding p-STAT3
immunopositive bands was quantified using densitometry. Data are represented as the average of at least triplicated independent experiments±SEM. (B) Cellular
proliferation of 1 day starved (DMEMwith 0.1% FBS) VSMCswas induced by HB-EGF (10 ng/ml) for 24 h. To examine the effects of EGFR inhibitor and JAK-STAT
pathway inhibitors on HB-EGF induced proliferation, an EGFR inhibitor AG1478 (250 nM), a JAK2 inhibitor AG490 (10 μM), and STAT3 inhibitor peptide (10 and
50 μM) were added to the medium 1 h prior to HB-EGF treatment. Data are represented as the average of at least triplicated independent experiments±SEM. ⁎Pb0.05.
Fig. 2. HB-EGF induces mRNA expression of IL-6 family cytokines. (A) VSMCs were stimulated with HB-EGF (10 ng/ml), and collected at the time indicated. Total
mRNAs were prepared and the mRNA expressions of IL-6, CT-1, LIF and CNTF were evaluated by RT-PCR using specific primers. Relative expressions of these
genes were quantified in the three panels at the bottom. (B) HB-EGF (10 ng/ml) conditioned media were collected at the time indicated, and the concentration of IL-6 in
the each medium was determined by ELISA. Data are represented as the average of at least triplicated independent experiments±SEM. ⁎Pb0.05.
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subjected to western blot using p-STAT3 specific antibody.
According to our western blot analysis, HB-EGF induced
STAT3 phosphorylation as early as 5 min which decreased to
the baseline thereafter. However, STAT3 phosphorylation was
observed again after 60 min (Fig. 1A).
We also performed BrdU incorporation assay 24 h after HB-
EGF (10 ng/ml) treatment to evaluate its effect on VSMC
proliferation. HB-EGF induced significant VSMC proliferation.
AG1478, an EGFR tyrosine kinase inhibitor (250 nM),
inhibited HB-EGF induced cell proliferation. Furthermore,
10 μM of AG490, a JAK2 inhibitor, and 10 to 50 μM of STAT3
inhibitor peptide also inhibited HB-EGF induced VSMC
proliferation indicating JAK-STAT pathway was involved inFig. 3. HB-EGF induces IL-6 secretion and cellular proliferation via NF-κB pathw
of pretreatment of various signal pathway inhibitors (wor, 100 nM of wortmannin; P
Bay, 2.5 μM of Bay117082). The cells were collected 45 min after HB-EGF stimulat
(B) IL-6 secretion was induced by HB-EGF (10 ng/ml) for 1 h. NF-κB inhibitor Bay1
collected 1 h after the HB-EGF treatment, and the concentration of IL-6 in the med
translocation into the nucleus, the cells were collected at the time indicated and prepar
western blot using p65 and IκBα specific antibodies. (D) To examine the effect of Ba
after HB-EGF (10 ng/ml) treatment and prepared for western blot. Both nuclear frac
specific antibodies. (E) After 24 h of starvation, NF-κB pathway was blocked by 1 h o
by HB-EGF (10 ng/ml). The cells were collected 24 h after for BrdU incorporatio
experiments±SEM. ⁎Pb0.05.HB-EGF induced VSMC proliferation. When used without HB-
EGF stimulation, no significant effect of AG1478, AG490, or
STAT3 inhibitor peptide treatment on VSMC proliferation was
observed (Fig. 1B).
3.2. HB-EGF up-regulates IL-6 mRNA expression and
augments IL-6 secretion
Because IL-6 has been implicated in the activation of STAT3,
we examined the effect ofHB-EGFon IL-6mRNAexpressions in
VSMCs. The expression of IL-6 mRNAwas increased after HB-
EGF treatment and peaked at 45min. Among other IL-6 family of
cytokine, CT-1, LIF and CNTF mRNA expression was increased
by HB-EGF treatment in a time dependent manner (Fig. 2A).ay. (A) VSMCs were stimulated by HB-EGF (10 ng/ml) with or without 1 h
D, 10 μM of PD98059; SB, 10 μM of SB203580; SP, 10 μM of SP600125; and
ion and subjected to RT-PCR using IL-6, CT-1, LIF and CNTF specific primers.
17082 (2.5 μM) was added 1 h prior to the HB-EGF treatment. The media were
ia was determined by ELISA. (C) To examine the effect of HB-EGF on NF-κB
ed for western blot. Both nuclear fraction and cytosolic fraction were subjected to
y117082 on HB-EGF induced NF-κB activation, the cells were collected 30 min
tion and cytosolic fraction were subjected to western blot using p65 and IκBα
f Bay117082 pretreatment (1 and 2.5 μM) and cellular proliferation was induced
n assay. Data are represented as the average of at least triplicated independent
1641K.-S. Lee et al. / Biochimica et Biophysica Acta 1773 (2007) 1637–1644However, oncostatin M and IL-11 mRNA were not detected by
HB-EGF treatment (data not shown). We also measured the
changes in the concentration of IL-6 in the medium after HB-EGF
treatment for 1 to 3 h. As shown in Fig. 2B, IL-6 secretion was
augmented in VSMCs in a time-dependent manner.
3.3. NF-κB mediates HB-EGF induced IL-6 family cytokines
gene expression and IL-6 secretion in VSMCs
To determine which signaling pathway was activated in HB-
EGF induced IL-6 secretion, cells were incubated with HB-EGF
in the presence of various cell signaling molecule inhibitors
(PI3K inhibitor: wortmannin 100 nM, ERK inhibitor: PD98059
10 μM, p38 MAP kinase inhibitor: SB203580 10 μM, JNK
inhibitor: SP600125 10 μM, NF-κB inhibitor: Bay117082
2.5 μM). We found that blockage of NF-κB pathway byFig. 4. HB-EGF induces late STAT3 activation via NF-κB dependent IL-6 secretion
1 μg/ml of IL-6 neutralizing antibody for 1 h. (A) STAT3 activation was induced by 1
using p-STAT3 specific antibody. (B) After 5 min treatment of HB-EGF, cell lysate
immunoprecipitated with antibody to gp130, and then subjected to western blot usin
independent experiments±SEM. ⁎Pb0.05.Bay117082 significantly abolished the HB-EGF-mediated
stimulation of IL-6 mRNA expression and IL-6 secretion (Fig.
3A and B), while no significant effect by other signal pathway
inhibitors was observed. For other IL-6 family cytokines such as
CT-1 and CNTF, similar pattern was observed. For LIF,
wortmannin, PD98059, SB203580, and SP600125 treatment
inhibited HB-EGF induced mRNA expression although the
effect was not significant as that produced by Bay117082. Next,
we examined whether NF-κB signal pathway was involved in
HB-EGF induced VSMC proliferation using western blot and
BrdU incorporation assay. NF-κB translocation to the nucleus
was increased from 15 min after the HB-EGF treatment (Fig.
3C), and NF-κB pathway inhibitor Bay117082 decreased HB-
EGF induced translocation of p65 (Fig. 3D). HB-EGF induced
VSMC proliferation was significantly repressed by Bay117082
treatment (Fig. 3E).. One day starved VSMCs were pretreated with either 2.5 μM of Bay117082 or
h of HB-EGF (10 ng/ml) treatment, and the cells were prepared for western blot
s were subjected to western blot using p-STAT3 antibody. (C) The lysates were
g p-tyrosine antibody. Data are represented as the average of at least triplicated
Fig. 6. IL-6 plays an important role in HB-EGF induced VSMC proliferation and
STAT3 activation. After 24 h of starvation, the cells were pretreated with IL-6
neutralizing antibody (1 μg/ml) for 1 h then cellular proliferation was induced by
HB-EGF (10 ng/ml). The cells were collected 24 h after for BrdU incorporation
assay. Data are represented as the average of at least triplicated independent
experiments±SEM. ⁎Pb0.05.
1642 K.-S. Lee et al. / Biochimica et Biophysica Acta 1773 (2007) 1637–16443.4. Delayed STAT3 activation is mediated by NF-κB and IL-6
The cell lysates were subjected to western blot for deter-
mining STAT3 activation. HB-EGF-induced delayed phosphor-
ylation of STAT3 was dramatically attenuated by Bay117082
and IL-6 neutralizing antibody treatment (Fig. 4A). However,
1 h of pretreatment with Bay117082 or IL-6 neutralizing
antibody had no significant effect on HB-EGF induced early
STAT3 phosphorylation (Fig. 4B). One hour of HB-EGF
treatment phosphorylated gp130, a common receptor subunit of
IL-6 family cytokine, and this was also inhibited by Bay117082
and IL-6 neutralizing antibody (Fig. 4C). To determine whether
the HB-EGF conditioned media could induce phosphorylation
of STAT3, we stimulated cells for 15 min with HB-EGF
conditioned media. Conditioned media (stimulated with HB-
EGF for 1 h) phosphorylated STAT3 and this STAT3 activation
was significantly attenuated by IL-6 neutralizing antibody
treatment indicating HB-EGF induced delayed STAT3 activa-
tion was mediated by IL-6. Purified 100 pg/ml of IL-6 treatment
also increased phosphorylation of STAT3 (Fig. 5).
3.5. IL-6 neutralizing antibody attenuates HB-EGF-induced
cell proliferation in VSMC
The cells were pretreated with IL-6 neutralizing antibody for
1 h. BrdU incorporation assay was performed after 24 h of HB-
EGF treatment. IL-6 neutralizing antibody significantly inhib-
ited HB-EGF-induced proliferation of VSMCs (Fig. 6). NoFig. 5. IL-6 neutralizing antibody inhibits HB-EGF-conditioned media induced
STAT3 activation. STAT3 activation was induced by HB-EGF conditioned
media (10 ng/ml, 1 h) with or without IL-6 neutralizing antibody (1 μg/ml). The
cells were collected 15 min after the stimulation for western blot using p-STAT3
specific antibody. Purified IL-6 (100 pg/ml) was used as a positive control. Data
are represented as the average of at least triplicated independent experiments±
SEM. ⁎Pb0.05.significant effect of IL-6 neutralizing antibody itself on VSMC
proliferation was observed.
4. Discussion
HB-EGF has been known to induce VSMC proliferation, and
this involves PI3K-Akt and MAPK pathway [11,12]. We also
confirmed that PI3K-Akt, and ERK signal pathways were
involved in HB-EGF induced VSMCs proliferation (data not
shown). In addition, our preliminary data showed that a JAK2
inhibitor AG490 and STAT3 inhibitor peptide inhibited HB-
EGF induced VSMC proliferation suggesting JAK-STAT path-
way was also involved in HB-EGF-induced VSMC prolifera-
tion. A variety of cytokines, lymphokines and growth factors
utilize JAK-STAT signaling pathway to transmit extracellular
signals to the nucleus. JAK-STAT activation stimulates
cell proliferation, differentiation, migration and apoptosis
[34]. Nevertheless, relatively less has been known regarding
JAK-STAT pathway in HB-EGF induced VSMC proliferation
to date.
In the present study, HB-EGF induced STAT3 phosphoryla-
tion was observed at 5 min then decreased to the baseline
thereafter. However, at 60 min, secondary STAT3 phosphory-
lation was occurred. Thus, in this study, we tried to elucidate the
underlying mechanism of this biphasic activation of STAT3
pathway induced by HB-EGF. IL-6, a proinflammatory cytokine
and a representative member of IL-6 family of cytokine along
with LIF, CT-1, CNTF, oncostatinM, and IL-11, has been known
to play an important role in STAT3 activation [22,35]. Also,
many previous studies have reported that the delayed STAT3
activation induced by AngII or isoproterenol in cardiomyocytes
was due to the secretion of IL-6 family cytokines [13,14]. In
agreement with these reports, our data showed that HB-EGF
treatment caused delayed STAT3 activation, and increased
mRNA expression of IL-6 as well as other IL-6 family of
1643K.-S. Lee et al. / Biochimica et Biophysica Acta 1773 (2007) 1637–1644cytokine CT-1, LIF and CNTF in a time dependent manner.
Next, we measured the level of IL-6 in HB-EGF conditioned
media by ELISA kit. Our result shows that, compared to control
group, HB-EGF treatment increased IL-6 secretion approxi-
mately 3 folds at 60 min, the time point where delayed STAT3
activation occurred. One previous study reported that the
concentration of IL-6 in the conditioned media stimulated with
AngII for 2 h was about 80 pg/ml and this caused STAT3
activation in cardiomyocytes [14]. In our study, HB-EGF-
stimulated conditioned media induced STAT3 phosphorylation,
and this was inhibited by IL-6 neutralizing antibody treatment.
Also 100 pg/ml of IL-6, the same concentration of IL-6 secreted
by HB-EGF treatment, induced significant STAT3 activation.
This suggests that IL-6 was a critical autocrine/paracrine factor
that mediated HB-EGF-induced biphasic activation of STAT3 in
our study. Unfortunately, due to the lack of established method
directly measuring the level of CT-1 and LIF in the media or
commercially available CT-1 and LIF inhibitors, we were unable
to determine the effect of CT-1 and LIF on HB-EGF induced
VSMC proliferation.
Previous studies have reported that gp130, an important
mediator of IL-6 signaling pathway, is not normally expressed
and IL-6/IL-6Rα complex is required to up-regulate its ex-
pression in human VSMC [36,37]. However, in our study, we
observed even untreated rat VSMC expresses both IL-6Rα (RT-
PCR) and gp130 (RT-PCR and western blot). In fact, cognate
expression of IL-6Rα in aortic smooth muscle of mice has been
recently reported [38]. At this moment, we can only speculate
that this discrepancy is due to the difference of species.
Many previous studies have reported that stress or growth
factors induced secretion of cytokines including IL-6 via NF-κB
dependent pathway in various cell types [39–41]. Thus we also
examined whether HB-EGF induced IL-6 family cytokine
expressions employed NF-κB pathway, or other pathways such
as PI3K-Akt or MAP kinase pathway, by evaluating the effect
of various signal pathway inhibitors on IL-6 family cytokine
mRNA expressions. According to our data, Bay117082, a NF-
κB selective inhibitor, significantly inhibited HB-EGF induced
IL-6, CT-1, LIF and CNTF mRNA expression. Furthermore,
Bay117082 also inhibited subsequent IL-6 secretion and
delayed STAT3 activation.
In addition, to evaluate the role of NF-κB pathway in HB-
EGF induced VSMC proliferation, we performed western blot
analysis. HB-EGF treatment increased translocation of NF-κB
into nucleus at 15 min and subsequent cellular proliferation, and
both the translocation of NF-κB and cellular proliferation were
abrogated by Bay117082 treatment. Furthermore, this proposed
sequence of events; EGFR activation by HB-EGF, NF-κB
activation, IL-6 secretion, delayed STAT3 activation, and
VSMC proliferation was confirmed indirectly by the fact that
IL-6 neutralizing antibody pretreatment significantly inhibited
HB-EGF induced VSMC proliferation.
Based on the findings of the present study, we report that
HB-EGF stimulation leads to delayed phosphorylation of
STAT3 via NF-κB dependent IL-6 secretion in VSMCs. Our
findings will help us better understand the molecular mecha-
nism of HB-EGF induced proliferation of VSMCs.Acknowledgement
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